Moshkevich Solomon, an officer at Natera, Inc., has reported the sale of shares in the company to satisfy tax obligations related to the vesting of restricted stock units (RSUs). This action, documented in a recent SEC filing, highlights Solomon's strategic financial management within the medical laboratories sector.

Background

Natera, Inc. is a prominent company in the medical laboratories industry, classified under the Standard Industrial Classification (SIC) code 8071. The company is based in Austin, Texas, and focuses on providing advanced genetic testing services. Solomon's recent filing is part of a series of transactions he has made in connection with his role at Natera. The most recent filings include Form 4 on October 29, 2026, and Form 144 on October 28, 2026.

What the Filing Says

The SEC filing, dated October 29, 2026, details two transactions involving the sale of common stock. On October 27, Solomon sold 1,010 shares at a price of $406 per share. The following day, he sold an additional 1,162 shares at $426.34 per share. These sales were made to meet tax withholding obligations related to the vesting of RSUs.

The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Impact

These transactions may affect Natera's stock performance and investor sentiment, particularly among stakeholders who monitor executive actions closely. Solomon's role as an officer means that his financial decisions can reflect the company's overall health and management strategy.

What's Next

The filing does not say what happens next.